BioStock: Pila Pharma’s CEO on building the company since its IPO

“We’re on our way.” This is how Pila Pharma CEO Dorte X. Gram starts the 2021 year end report that was released last week. During the first half of the year as a public company, the focus has been on building the high-quality team that will drive the development of the drug candidate XEN-D0501, hopefully all the way to market. In connection with the newly released report, BioStock has contacted Gram to get her view of the past year.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/02/pila-pharmas-ceo-on-building-the-company-since-its-ipo/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se